Skip to content

Study · Animal study (in vivo) · rat · 1997

6 results

Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin.

De Gennaro Colonna V, Rossoni G, Bernareggi M, Müller EE, Berti F

European journal of pharmacology1 Sept 1997Cited by 51 (Europe PMC)

PMID9369349 (opens in a new tab)DOI10.1016/s0014-2999(97)01178-3 (opens in a new tab)PepBankPUB-09369349
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In GH-deficient rats, hexarelin restored the impaired somatotropic function to normal.

    In plain wordsIn GH-deficient rats, hexarelin restored the impaired growth hormone function to normal.

    Peptide
    Hexarelin
    Outcome
    IncreaseSomatotropic function in GH-deficient rats
    Study

    ratn: not reported in source

    Anti-GHRH serum-treated (GH-deficient) rats, perfused hearts
    Comparator
    Untreated GH-deficient rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    80 microg/kg, bid · subcutaneous · 15 daysAs given in this study (rat).

    Source sentences

    Summary
    Hexarelin (80 microg/kg, bid, s.c.), administered for 15 days to anti-GHRH serum-treated rats, restored to normal the impaired somatotropic function
    1 context sentence
    Summary · context
    The ability of hexarelin, an effective growth hormone (GH)-releasing hexapeptide, to reverse the worsening of cardiac dysfunction in GH-deficient animals was studied in young male rats passively immunized by administration of an anti-GH-releasing hormone (GHRH) serum.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In GH-deficient rats, hexarelin counteracted ischemic damage and improved postischemic left ventricular developed pressure to values higher than those of controls.

    In plain wordsIn GH-deficient rats, hexarelin reduced heart damage from low blood flow and improved heart pressure recovery above control levels.

    Peptide
    Hexarelin
    Outcome
    IncreasePostischemic left ventricular developed pressure
    Study

    ratn: not reported in source

    Anti-GHRH serum-treated (GH-deficient) rats, perfused hearts
    Comparator
    Untreated GH-deficient rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    80 microg/kg, bid · subcutaneous · 15 daysAs given in this study (rat).

    Source sentences

    Summary
    and counteracted the ischemic damage, improving postischemic left ventricular developed pressure to values higher than those of controls.
    1 context sentence
    Summary · context
    The ability of hexarelin, an effective growth hormone (GH)-releasing hexapeptide, to reverse the worsening of cardiac dysfunction in GH-deficient animals was studied in young male rats passively immunized by administration of an anti-GH-releasing hormone (GHRH) serum.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In GH-deficient rats, hexarelin brought the generation of 6-keto-PGF1alpha back to that of control preparations.

    In plain wordsIn GH-deficient rats, hexarelin brought the heart's prostacyclin production back to control levels.

    Peptide
    Hexarelin
    Outcome
    Increase6-keto-PGF1alpha generation in perfused hearts
    Study

    ratn: not reported in source

    Anti-GHRH serum-treated (GH-deficient) rats, perfused hearts
    Comparator
    Untreated GH-deficient rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    80 microg/kg, bid · subcutaneous · 15 daysAs given in this study (rat).

    Source sentences

    Summary
    Furthermore, both the generation of 6-keto-PGF1alpha and the vasopressor activity of angiotensin II reverted to those of control preparations.
    2 context sentences
    Summary · context
    a decreased rate of formation of 6-keto-prostaglandin F1alpha (6-keto-PGF1alpha), a stable metabolite of prostacyclin, in perfusates from preischemic and reperfusion periods
    Summary · context
    The ability of hexarelin, an effective growth hormone (GH)-releasing hexapeptide, to reverse the worsening of cardiac dysfunction in GH-deficient animals was studied in young male rats passively immunized by administration of an anti-GH-releasing hormone (GHRH) serum.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In GH-deficient rats, hexarelin brought the vasopressor activity of angiotensin II back to that of control preparations.

    In plain wordsIn GH-deficient rats, hexarelin brought the heart's blood vessel response to angiotensin II back to control levels.

    Peptide
    Hexarelin
    Outcome
    DecreaseAngiotensin II vasopressor activity in perfused hearts
    Study

    ratn: not reported in source

    Anti-GHRH serum-treated (GH-deficient) rats, perfused hearts
    Comparator
    Untreated GH-deficient rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    80 microg/kg, bid · subcutaneous · 15 daysAs given in this study (rat).

    Source sentences

    Summary
    Furthermore, both the generation of 6-keto-PGF1alpha and the vasopressor activity of angiotensin II reverted to those of control preparations.
    2 context sentences
    Summary · context
    an increased vasopressor activity of angiotensin II.
    Summary · context
    The ability of hexarelin, an effective growth hormone (GH)-releasing hexapeptide, to reverse the worsening of cardiac dysfunction in GH-deficient animals was studied in young male rats passively immunized by administration of an anti-GH-releasing hormone (GHRH) serum.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In control rats, hexarelin considerably improved postischemic ventricular function of perfused hearts.

    In plain wordsIn rats with normal growth hormone, hexarelin improved heart function recovery after low blood flow.

    Peptide
    Hexarelin
    Outcome
    IncreasePostischemic ventricular function in control rats
    Study

    ratn: not reported in source

    Control rats, perfused hearts
    Comparator
    Untreated control rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    80 microg/kg, bid · subcutaneous · 15 daysAs given in this study (rat).

    Source sentences

    Summary
    Administration of hexarelin to control rats induced a considerable improvement of postischemic ventricular function of the perfused hearts which was similar to that present in preparations from anti-GHRH serum-treated rats given hexarelin.
    1 context sentence
    Summary · context
    The ability of hexarelin, an effective growth hormone (GH)-releasing hexapeptide, to reverse the worsening of cardiac dysfunction in GH-deficient animals was studied in young male rats passively immunized by administration of an anti-GH-releasing hormone (GHRH) serum.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In rats, the protective activity of hexarelin was divorced from any further stimulation of somatotropic function.

    In plain wordsIn rats, the heart protection from hexarelin did not depend on further growth hormone stimulation.

    Peptide
    Hexarelin
    Outcome
    No significant changeSomatotropic stimulation behind the cardioprotective effect
    Study

    ratn: not reported in source

    Anti-GHRH serum-treated (GH-deficient) rats, perfused hearts
    Comparator
    Untreated GH-deficient rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    80 microg/kg, bid · subcutaneous · 15 daysAs given in this study (rat).

    Source sentences

    Summary
    This protective activity was divorced from any further stimulation of somatotropic function.
    1 context sentence
    Summary · context
    The ability of hexarelin, an effective growth hormone (GH)-releasing hexapeptide, to reverse the worsening of cardiac dysfunction in GH-deficient animals was studied in young male rats passively immunized by administration of an anti-GH-releasing hormone (GHRH) serum.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.